Trial Profile
A clinical study of CS1003 in solid tumor patients in USA
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 31 Oct 2018
Price :
$35
*
At a glance
- Drugs Nofazinlimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Oct 2018 New trial record
- 23 Oct 2018 According to a CStone Pharmaceuticals media release, the US FDA has granted approval to the company's Investigational New Drug (IND) application.